A review highlighted CB1's potential in treating excitotoxicity and addiction, and CB2's potential in ALS, HIV neuroinflammation, and osteoporosis, while emphasizing the need for receptor-selective drugs.
Read this if you are interested in the future of cannabinoid-based medicines beyond pain and nausea.
CB2 selectivity: key to avoiding psychoactive side effects
What the researchers found
This minireview examined therapeutic opportunities from modulating CB1 and CB2 receptors across several disease areas.
For CB1: the receptor protects against excitotoxic brain damage, and CB1 modulation could limit addiction liability. CB1 also influences insulin release, insulin resistance, and feeding behavior, connecting it to diabetes and obesity.
For CB2: the receptor's presence on immune cells makes it relevant to ALS (where inflammatory cell activation drives motor neuron death), HIV-related neuroinflammation, and postmenopausal osteoporosis (where CB2 modulation affects bone remodeling).
The review emphasized that achieving receptor selectivity is essential for safe therapeutics, as CB1 activation causes psychoactive effects while CB2 modulation generally does not.
Why it matters
This review mapped out the most promising clinical applications for cannabinoid receptor modulation, showing that CB1 and CB2 offer complementary therapeutic opportunities across very different disease areas.
The numbers in context
Disease areas: excitotoxicity (CB1), addiction (CB1), diabetes/obesity (CB1), ALS (CB2), HIV neuroinflammation (CB2), osteoporosis (CB2)
How the study worked
Minireview synthesizing preclinical and clinical evidence on CB1 and CB2 receptor roles in specific disease states: excitotoxicity, addiction, metabolic disorders, ALS, HIV neuropathology, and osteoporosis.
What this study cannot tell us
Minireview covering broad territory with limited depth per topic. Many therapeutic applications remained in preclinical stages. The failure of rimonabant (CB1 antagonist for obesity) illustrated the difficulty of translating cannabinoid research to safe drugs.
How to read the evidence
Review in a leading endocrinology journal providing a roadmap of therapeutic opportunities, based on varying levels of preclinical and early clinical evidence.
When this study was published
Published in 2015. Progress on selective cannabinoid receptor drugs has been mixed since.
The bigger picture
The challenge in cannabinoid therapeutics is separating beneficial effects from unwanted ones. CB2-selective drugs may be the most promising path because they could treat inflammation, neurodegeneration, and bone disease without psychoactive effects.
Questions still open
- Can CB2-selective drugs avoid the psychiatric side effects that plagued CB1-targeted obesity drugs? Would allosteric modulators offer better therapeutic windows than direct agonists/antagonists? How close are cannabinoid-based drugs for ALS or osteoporosis to clinical trials?
Common questions
What is the difference between CB1 and CB2 receptors?
Could cannabinoids treat osteoporosis?
Read the original research
Minireview: From the bench, toward the clinic: therapeutic opportunities for cannabinoid receptor modulation.
Molecular endocrinology (Baltimore, Md.), 29(6), 801-13
Citation
Picone, Robert P; Kendall, Debra A. (2015). Minireview: From the bench, toward the clinic: therapeutic opportunities for cannabinoid receptor modulation.. Molecular endocrinology (Baltimore, Md.), 29(6), 801-13. https://doi.org/10.1210/me.2015-1062
Explore the wider topic
- How THC Affects Your Amygdala: The Brain's Threat Detector and Cannabis
- The Anandamide Connection: Your Body's Natural Bliss Molecule
- How Long for Cannabinoid Receptors to Return to Normal
- Cannabis and the Developing Brain: What Every Teenager (and Parent) Should Know
- Why Can't I Enjoy Anything Without Weed? The Science Behind It
- Dopamine Recovery After Quitting Weed: What the Science Says
- The Endocannabinoid System Explained Simply: What It Does and Why It Matters
- Your Endocannabinoid System Explained: Why Withdrawal Happens
- Your Nervous System After Quitting Weed: Fight or Flight
- Using Weed Under 18: What It Does to Your Developing Brain
- What THC Does to Your Brain: Why Withdrawal Happens
- THC and Your Prefrontal Cortex: What Cannabis Does to Your Decision-Making Brain
- Weed, Cortisol, and Stress: What Cannabis Does to Your Stress Hormones
- Weed and Memory: What the Science Says About THC and Your Hippocampus
- Weed and Motivation: Is Amotivational Syndrome Real?
- Weed and Your Nervous System: What THC Actually Does to Your Brain and Body
- How Weed Rewires Your Reward System (And How to Reset It)